Influences of targeted exercise therapy on treatment-related side effects of hormonetherapy in prostate cancer patients

Not Applicable

Conditions: C61
Malignant neoplasm of prostate

Registration Number: DRKS00009975

Lead Sponsor: Deutsche Sporthochschule zu Köln

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Male

Target Recruitment: 60

Inclusion Criteria

Prostate cancer patients who have received hormone therapy continuously at least over a period of 3 months and a maximum of 12 months. The treatment needs to be continue for at least one year. Half of the patients ( n = 30) received Leuprone® , the other half ( n = 30) alternative hormonal therapies.

Serum testosterone levels < 0,50ng / ml (range castration)

Age > 18

singed informed consent

Exclusion Criteria

ongoing medication with tricyclic antidepressants and duloxetine (Yentreve)

WHO / ECOG performance status> 2

Planned OP

Life expectancy <6 months

All disease situations that do not allow a sporting activity, in particular:
Clinically manifest heart failure (NYHA III-IV)
Respiratory partial or global failure
Durable thrombocytopenia <10,000 / ul, for example, Autoimmunthrombozytopenien intractable.
Congenital or acquired thrombocytopenia or any coagulation disorder.
Symptomatic CHD (possibly performing exercise ECG is recommended)
Severe intractable hypertension
Not adjustable COPD
Uncontrolled cerebral convulsions
CNS metastases
Medical or mental state that leads the investigator to not allowing the patient to participate in the study. or a legally binding signature of the consent form does

Unwillingness to storage and transfer of personal data in the context of the study protocol.

Participation in another sport-study

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Strength: dynamically on a isokinetic dynamometer<br><br>Measurements: Baseline, 3, 6 and 12 months, and 6 and 12 months follow-up

Secondary Outcome Measures

Name	Time	Method
Endurance with a 30/15 Test on a bicycle ergometer<br>Quality of life via a questionnaire (EORTC QLQ - C30 and PR25)<br>Fatigue via a questionnaire (MFI)<br>Body composition via BIA (bioelectrical impedance analysis)<br>erectile dysfunction via a questionnaire (IIEF)<br>bone pain via a questionnaire (FACT- BP)<br>Activity level via questionnaires (QPAQ and KAS )<br>BMI<br>BMD via DXA scan<br>PSA and testosterone value<br><br>Measurement timing: See primary endpoint, except bone density<br>BMD measurements: baseline, after 12 months and 12 months follow -up